Warfarin and Other Coumarin Derivatives: Pharmacokinetics, Pharmacodynamics, and Drug Interactions

 

 Buy Article Permissions and Reprints

ABSTRACT

Warfarin, a racemic mixture of R- and S-enantiomers, exerts its anticoagulant effect by interfering with the hepatic synthesis of vitamin K-dependent clotting factors II, VII, IX, and X and proteins C and S. Warfarin displays stereospecific pharmacokinetic and pharmacodynamic properties, and the isomers are differentially metabolized by cytochrome p450 isozymes. Among patients treated with warfarin, there is little correlation among dose, serum concentration, and therapeutic effect, necessitating individualized dosing guided by therapeutic monitoring of the prothrombin time. The pharmacokinetic and pharmacodynamic properties of warfarin as well as its narrow therapeutic index make it particularly susceptible to interactions with other prescription and nonprescription drugs, including dietary supplements. Numerous drug compounds are reported to interact with warfarin, necessitating increased prothrombin time monitoring and warfarin dosing adjustments to maintain safe and effective anticoagulation.

REFERENCES

• 1 Roderick L M. A problem in the coagulation of blood: sweet clover disease of cattle.  Am J Physiol . 1931;  96 413-425
  PubMedGoogle Scholar
• 2 Campbell H A, Link K P. Studies on the hemorrhagic sweet clover disease IV: the isolation and crystallization of the hemorrhagic agent.  J Biol Chem . 1941;  138 21-33
  PubMedGoogle Scholar
• 3 Stahman M A, Huebner C F, Link K P. Studies on the hemorrhagic sweet clover disease V: identification and synthesis of the hemorrhagic agent.  J Biol Chem . 1941;  138 513-527
  PubMedGoogle Scholar
• 4 Link K P. The discovery of dicoumarol and its sequels.  Circulation . 1959;  19 97-107
  CrossrefPubMedGoogle Scholar
• 5 Majerus P W, Broze G J, Miletich J P, Tollefsen D M. Anticoagulant, thrombolytic, and antiplatelet agents. In: Goodman L, Gilman A, et al., eds. The Pharmacologic Basis of Therapeutics New York: Pergamon Press; 1990
  Google Scholar
• 6 O'Reilly R A. Studies on the optical enantiomorphs of warfarin in man.  Clin Pharmacol Ther . 1974;  16 348-354
  PubMedGoogle Scholar
• 7 Thijjsen H HW, Baars L GM, Vervoort H TM. Vitamin 2,3-epoxide reductase: the basis for stereoselectivity of 4-hydroxycoumarin anticoagulant activity.  Br J Pharmacol . 1988;  95 675-682
  PubMedGoogle Scholar
• 8 Suttie J W. Vitamin K dependent carboxylation of glutamyl residues of proteins.  Biofactors . 1988;  1 55-60
  PubMedGoogle Scholar
• 9 Whitlon D S, Sadowski J A, Suttie J W. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition.  Biochemistry . 1978;  17 1371-1377
  CrossrefPubMedGoogle Scholar
• 10 Vermeer C, Hamulyak K. Pathophysiology of vitamin K deficiency and oral anticoagulants.  Thromb Haemost . 1991;  66 153-159
  PubMedGoogle Scholar
• 11 Fasco M J, Hildebrandt E F, Suttie J W. Evidence that warfarin anticoagulant action involves two distinct reductase activities.  J Biol Chem . 1982;  257 11210-11212
  PubMedGoogle Scholar
• 12 Malhotra O P, Nesheim M E, Mann K G. The kinetics of activation of normal and gamma-carboxyglutamic acid-deficient prothrombins.  J Biol Chem . 1985;  260 279-287
  PubMedGoogle Scholar
• 13 Pyoralak K, Jussila J, Mustala O, Siurala M. Absorption of warfarin from stomach and small intestine.  Scand J Gastroenterol . 1971;  6 (suppl 9) 95-103
  PubMedGoogle Scholar
• 14 Stirling U, Howarth D J, Stockley R. et al . Comparison of the bioavailabilities and anticoagulant activities of two warfarin formulations.  Br J Haematol . 1982;  51 37-45
  PubMedGoogle Scholar
• 15 O'Reilly R A, Welling P G, Wagner J G. Pharmacokinetics of warfarin following intravenous administration in man.  Thromb Haemost . 1971;  25 178-186
  PubMedGoogle Scholar
• 16 Hewick D S, McEwen J. Plasma half-lives, plasma metabolites, and anticoagulant efficacies of the enantiomers of warfarin in man.  J Pharm Pharmacol . 1983;  25 458-465
  PubMedGoogle Scholar
• 17 O'Reilly R. Interaction of the anticoagulant drug warfarin and its metabolites with human plasma albumin.  J Clin Invest . 1969;  48 193-202
  PubMedGoogle Scholar
• 18 Chan E, McLachlan A J, Pegg M. et al . Disposition of warfarin enantiomers and metabolism in patients during multiple dosing with racemic warfarin.  Br J Clin Pharmacol . 1994;  37 563-569
  PubMedGoogle Scholar
• 19 Yacobi A, Udall J A, Levy G. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect.  Clin Pharmacol Ther . 1976;  19 552-558
  PubMedGoogle Scholar
• 20 Yacobi A, Stoll R G, DiSanto R, Levy G. Intrasubject variation of warfarin binding in serum of normal subjects.  Res Commun Chem Pathol Pharmacol . 1976;  14 743-746
  PubMedGoogle Scholar
• 21 Ganeval D, Fischer A M, Barre J. et al . Pharmacokinetics of warfarin in the nephritic syndrome and effect on vitamin K dependent clotting factors.  Clin Nephrol . 1986;  25 75-80
  PubMedGoogle Scholar
• 22 Routledge P A, Chapman P H, Davies D M, Rawlins M D. Pharmacokinetics and pharmacodynamics of warfarin at steady state.  Br J Pharmacol . 1979;  8 243-247
  PubMedGoogle Scholar
• 23 Lewis R J, Trager W F. Warfarin metabolism in man: identification of metabolites in urine.  J Clin Invest . 1970;  49 907-913
  PubMedGoogle Scholar
• 24 Lewis R J, Trager W F, Chan K K. et al . Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone.  J Clin Invest . 1974;  53 1607-1617
  PubMedGoogle Scholar
• 25 Rettie A E, Korzekwa K R, Kunze K L. et al . Hydroxylation of warfarin by human cDNA-expressed cytochrome p450: a role for p450-2C9 in the etiology of S-warfarin drug interactions.  Chem Res Toxicol . 1992;  5 54-59
  CrossrefPubMedGoogle Scholar
• 26 Lewis R J, Trager W F, Robinson A J, Chan K K. Warfarin metabolites: the anticoagulant activity and pharmacology of warfarin alcohols.  J Lab Clin Med . 1973;  81 925-931
  PubMedGoogle Scholar
• 27 Breckenridge A, Orme M, Wesseling H. et al . Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man.  Clin Pharmacol Ther . 1973;  15 424-430
  PubMedGoogle Scholar
• 28 Wingard L B, O'Reilly R A, Levy G. Pharmacokinetics of warfarin enantiomers: a search for intrasubject correlations.  Clin Pharmacol Ther . 1978;  23 212-217
  PubMedGoogle Scholar
• 29 Hignite C, Uetriecht J, Tschanz C, Azaroff D. Kinetics of R and S warfarin enantiomers.  Clin Pharmacol Ther . 1980;  28 99-105
  PubMedGoogle Scholar
• 30 Godbillon J, Richard J, Gerardin A. et al . Pharmacokinetics of the enantiomers of acenocoumarol in man.  Br J Clin Pharmacol . 1981;  12 621-629
  CrossrefPubMedGoogle Scholar
• 31 Haustein K O. Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon.  Semin Thromb Haemost . 1999;  25 5-11
  PubMedGoogle Scholar
• 32 Choondara I A, Haynes B P, Cholerton S. et al . Enantiomers of warfarin and vitamin K1 metabolism.  Br J Clin Pharmacol . 1986;  22 729-732
  PubMedGoogle Scholar
• 33 Weiss P, Soff G A, Halkin H, Seligsohn U. Decline of proteins C and S and factors II, VII, IX and X during initiation of warfarin therapy.  Thromb Res . 1987;  45 783-790
  CrossrefPubMedGoogle Scholar
• 34 Harrison L, Johnston M, Massicotte M P. et al . Comparison of 5mg and 10mg loading doses in initiation of warfarin therapy.  Ann Intern Med . 1997;  126 133-136
  PubMedGoogle Scholar
• 35 Kumar S, Haight J RM, Tate G. et al . Effect of warfarin on plasma concentrations of vitamin K dependent coagulation factors in patients with stable control and monitored compliance.  Br J Haematol . 1990;  74 82-85
  PubMedGoogle Scholar
• 36 Hotraphinyo K, Triggs E F, Maybloom B, Maclaine-Cross A. Warfarin sodium: steady state plasma levels and patient age.  Clin Exp Pharmacol Physiol . 1978;  5 143-149
  PubMedGoogle Scholar
• 37 Routledge P A, Chapman P H, Davies D M, Rawlins M D. Pharmacokinetics and pharmacodynamics of warfarin at steady state.  Br J Clin Pharmacol . 1979;  8 243-247
  PubMedGoogle Scholar
• 38 Hanston P, Wittkowsky A K. Warfarin drug interactions. In: Ansell JE, Oertel LB, Wittkowsky AK, eds. Managing Oral Anticoagulant Therapy: Clinical and Operational Guidelines Gaithersburg, MD: Aspen; 1997
  Google Scholar
• 39 Wells P S, Holbrook A m, Crowther N R, Hirsh J. Interactions of warfarin with drugs and food.  Ann Intern Med . 1994;  121 676-683
  PubMedGoogle Scholar
• 40 Freedman M D, Olatidoy A G. Clinically significant drug interactions with the oral anticoagulants.  Drug Safety . 1994;  10 381-394
  PubMedGoogle Scholar
• 41 Testa B, Jenner P. Inhibitors of cytochrome p450s and their mechanism of action.  Drug Metab Rev . 1981;  12 1-117
  PubMedGoogle Scholar
• 42 Cropp J S, Bussey H I. A review of enzyme induction of warfarin metabolism with recommendations for patient management.  Pharmacotherapy . 1997;  17 719-728
  PubMedGoogle Scholar
• 43 Wittkowsky A K. Drug interactions update: drugs, herbs, and oral anticoagulation.  J Thromb Thrombolysis . 2001;  12 67-71
  CrossrefPubMedGoogle Scholar
• 44 Higashi M, Veenstra D L, Wittkowsky A K. et al . Influence of CYP2C9 genetic variants on the risk of overanticoagulation and of bleeding events during warfarin therapy.  JAMA . 2002;  287 690-698
  PubMedGoogle Scholar
• 45 Rosenbaum M D, Blendon R J, Benson J. et al .Survey of Americans and dietary supplements. National Public Radio/ Henry J. Kaiser Family Foundation/Harvard University Kennedy School of Government; 1999
  Google Scholar
• 46 Eisenberg D M, Davis R B, Ettner S L. et al . Trends in alternative medicine use in the United States 1990-1997; results of a follow-up national survey.  JAMA . 1998;  280 1569-1575
  CrossrefPubMedGoogle Scholar
• 47 Kurtzweil P. An FDA Guide to Dietary Supplements. U.S. Food and Drug Administration Publ. No. 99-2323; January 1999
  Google Scholar
• 48 Bouttata J I, Nace A M. Safety issues with herbal medicinals.  Pharmacotherapy . 2000;  20 257-269
  CrossrefPubMedGoogle Scholar
• 49 Heck A M, DeWitt B A, Lukes A L. Potential interactions between alternative therapies and warfarin.  Am J Health Syst Pharm . 2000;  57 1221-1227
  PubMedGoogle Scholar
• 50 Vaes L P, Chyka P A. Interactions of warfarin with garlic, ginger, ginkgo or ginseng: nature of the evidence.  Ann Pharmacother . 2000;  34 1478-1482
  PubMedGoogle Scholar
• 51 Hoult J R, Paya M. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential.  Gen Pharmacol . 1996;  27 713-722
  CrossrefPubMedGoogle Scholar
• 52 Newell C A, Anderson L A, Phillipson J D. Herbal Medicinals: A Guide for Health Care Professionals.  London: Pharmaceutical Press; 1996
  Google Scholar